Simple Summary During the last two decades, collaborative translational studies utilizing
novel methodologies have dramatically advanced our understanding of multiple myeloma …

Simple Summary In the pathogenesis of multiple myeloma (MM), some exosomes act on
different cells in the bone marrow microenvironment, which can create an environment …

Objectives: To describe progressive corneal microcyst-like epithelial changes (MECs) that
developed in patients treated with the investigational drug belantamab mafodotin (belamaf) …

Purpose To describe structural changes in corneal epithelium using anterior segment optical
coherence tomography (AS-OCT) in two relapsed and refractory multiple myeloma (RRMM) …

Multiple myeloma (MM) is a common hematological malignancy with poorly understood
recurrence and relapse mechanisms. Notably, bortezomib resistance leading to relapse …

Lenalidomide and its analogs are well-known for treating multiple myeloma. In this work,
designed sulfide-modified lenalidomide and pomalidomide were synthesized and …

Daratumumab (DARA) is a human IgG-K monoclonal antibody (MoAb) targeting CD38 that
is approved alone or in combination with bortezomib and dexamethasone or lenalidomide …

PURPOSE The prognosis of relapsed and refractory multiple myeloma (RRMM) that is
refractory to bortezomib and lenalidomide is very poor wherein the median survival is …

Introduction Lenalidomide use in nearly all induction regimens for multiple myeloma (MM)
has led to the treatment of lenalidomide-refractory disease becoming one of the most …

(1) Background: The aim of our study was to analyze the possible relationship of ABCB1 and
CYP1A1 gene variants with susceptibility and outcome of multiple myeloma (MM);(2) …